Clinical trial
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
NCT00256282 · John P. Fruehauf, Other · Completed
Key facts
| NCT number | NCT00256282 |
|---|---|
| Title | Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma |
| Official title | A Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in Patients With Metastatic Malignant Melanoma |
| Lead sponsor | John P. Fruehauf, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | Vinorelbine, Docetaxel, Sargramostim |
| Enrollment | 52 |
| Start date | Apr 1, 2003 |
| Primary completion | Aug 1, 2012 |
| Completion | Aug 1, 2012 |
| First posted | Nov 21, 2005 |
| Last update posted | May 3, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: